BCLI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BCLI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Brainstorm Cell Therapeutics's Enterprise Value is $33.05 Mil. Brainstorm Cell Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-21.44 Mil. Therefore, Brainstorm Cell Therapeutics's EV-to-EBIT ratio for today is -1.54.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Brainstorm Cell Therapeutics's Enterprise Value is $33.05 Mil. Brainstorm Cell Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-21.17 Mil. Therefore, Brainstorm Cell Therapeutics's EV-to-EBITDA ratio for today is -1.56.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Brainstorm Cell Therapeutics's Enterprise Value is $33.05 Mil. Brainstorm Cell Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Brainstorm Cell Therapeutics's EV-to-Revenue ratio for today is .
The historical data trend for Brainstorm Cell Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brainstorm Cell Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Enterprise Value | Get a 7-Day Free Trial | 100.98 | 124.38 | 128.59 | 61.29 | 16.49 |
Brainstorm Cell Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Enterprise Value | Get a 7-Day Free Trial | 61.29 | 128.42 | 86.85 | 10.54 | 16.49 |
For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Brainstorm Cell Therapeutics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Brainstorm Cell Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
Enterprise Value (A: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 16.5135516 | + | 0 | + | 0.672 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0.603 | + | 0 | - | 1.3 |
= | 16.49 |
Brainstorm Cell Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as
Enterprise Value (Q: Dec. 2023 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 16.5135516 | + | 0 | + | 0.672 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0.603 | + | 0 | - | 1.3 |
= | 16.49 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brainstorm Cell Therapeutics (NAS:BCLI) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Brainstorm Cell Therapeutics's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 33.052 | / | -21.439 | |
= | -1.54 |
Brainstorm Cell Therapeutics's current Enterprise Value is $33.05 Mil.
Brainstorm Cell Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.44 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Brainstorm Cell Therapeutics's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 33.052 | / | -21.174 | |
= | -1.56 |
Brainstorm Cell Therapeutics's current Enterprise Value is $33.05 Mil.
Brainstorm Cell Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.17 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Brainstorm Cell Therapeutics's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 33.052 | / | 0 | |
= |
Brainstorm Cell Therapeutics's current Enterprise Value is $33.05 Mil.
Brainstorm Cell Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Brainstorm Cell Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Stacy Lindborg | officer: EVP, Head Global Clin Research | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019 |
Nir Naor | director | BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019 |
Kirk Taylor | officer: Chief Medical Officer | C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019 |
Menghisteab Bairu | director | C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019 |
Alla Patlis | officer: See Remarks | C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601 |
Anthony Waclawski | officer: See Remarks | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF THE AMERICAS 28TH FL, NEW YORK NY 10019 |
Chaim Lebovits | officer: Chief Executive Officer | 110 EAST 59TH STREET, NEW YORK NY 10019 |
David Setboun | officer: EVP and COO | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLOOR, NEW YORK NY 10019 |
Acc International Holdings Ltd. | other: Member of 10% owner group | MORGAN & MORGAN BUILDING, PASEA ESTATE, ROAD TOWN, TORTOLA D8 VG 1110 |
Sankesh Abbhi | director | 3119 PONCE DE LEON, UNIT C, CORAL GABLES FL 33134 |
Jacob A Frenkel | director | 188 E. 70TH ST., #29A, NEW YORK NY 10021 |
Arturo Araya | officer: Chief Commercial Officer | C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601 |
Preetam Shah | officer: EVP, CFO and Treasurer | C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019 |
Ralph Dr. Kern | officer: COO and Chief Medical Officer | C/O BRAINSTORM CELL THERAPEUTICS, INC., 3 UNIVERSITY PLAZA DRIVE, SUITE 320, HACKENSACK NJ 07601 |
Irit Arbel | director | 6 HADISHON STREEET, JERUSALEM, ISRAEL 96596 L3 00000 |
From GuruFocus
By PRNewswire • 12-13-2023
By PRNewswire • 12-05-2023
By PRNewswire • 11-28-2023
By PRNewswire • 12-04-2023
By PRNewswire • 12-08-2023
By PRNewswire • 12-19-2023
By PRNewswire • 12-27-2023
By PRNewswire • 01-02-2024
By PRNewswire • 12-01-2023
By PRNewswire • 12-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.